Zacks Investment Research upgraded shares of Selecta Biosciences (NASDAQ:SELB) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. They currently have $2.00 price objective on the stock.
According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
A number of other research analysts also recently issued reports on SELB. ValuEngine raised Selecta Biosciences from a sell rating to a hold rating in a report on Thursday, August 1st. Mizuho reaffirmed a buy rating and set a $4.00 price target on shares of Selecta Biosciences in a report on Sunday, August 11th. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $6.00 price target on shares of Selecta Biosciences in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. Selecta Biosciences presently has an average rating of Hold and an average price target of $7.17.
Selecta Biosciences stock traded down $0.03 during mid-day trading on Wednesday, hitting $1.46. The company had a trading volume of 151,682 shares, compared to its average volume of 156,117. The stock’s 50 day moving average price is $1.80 and its two-hundred day moving average price is $2.02. Selecta Biosciences has a 12 month low of $1.41 and a 12 month high of $16.00.
Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Thursday, August 8th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.07). The business had revenue of $0.01 million during the quarter. On average, equities research analysts predict that Selecta Biosciences will post -1.2 EPS for the current year.
Large investors have recently made changes to their positions in the company. Polaris Venture Management Co. V L.L.C. boosted its stake in Selecta Biosciences by 72.6% during the first quarter. Polaris Venture Management Co. V L.L.C. now owns 2,773,479 shares of the company’s stock valued at $6,573,000 after buying an additional 1,166,666 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Selecta Biosciences by 98.4% in the 2nd quarter. Renaissance Technologies LLC now owns 471,500 shares of the company’s stock valued at $844,000 after purchasing an additional 233,800 shares during the last quarter. Paloma Partners Management Co bought a new stake in shares of Selecta Biosciences in the 2nd quarter valued at approximately $275,000. Vanguard Group Inc. lifted its stake in shares of Selecta Biosciences by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,620,305 shares of the company’s stock valued at $2,901,000 after purchasing an additional 109,806 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Selecta Biosciences in the 2nd quarter valued at approximately $195,000. 46.44% of the stock is currently owned by hedge funds and other institutional investors.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Further Reading: What does EPS mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.